Targeted lung denervation modulates the mucosal epithelial transcriptome in COPD
Karthi Srikanthan, Loes Kistemaker, Dirk-Jan Slebos, Wolfgang Gesierich, Kaid Darwiche, Peter Bonta, Gaetan Deslee, Pallav Shah, Reinoud Gosens
Source: ERJ Open Res, 8 (4) 00146-2022; 10.1183/23120541.00146-2022
Abstract
Targeted lung denervation (TLD) is a novel treatment for COPD with evidence of a potential beneficial effect on exacerbation frequency [1]. It is a minimally invasive procedure involving the ablation of the airway nerve trunks of the vagus nerve that travel parallel to and outside the main bronchi, thereby reducing neuronal acetylcholine release. It has been postulated that TLD may share a similar mechanism of action with the inhaled long-acting muscarinic antagonists [2].
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Karthi Srikanthan, Loes Kistemaker, Dirk-Jan Slebos, Wolfgang Gesierich, Kaid Darwiche, Peter Bonta, Gaetan Deslee, Pallav Shah, Reinoud Gosens. Targeted lung denervation modulates the mucosal epithelial transcriptome in COPD. ERJ Open Res, 8 (4) 00146-2022; 10.1183/23120541.00146-2022
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|